1. Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome?
- Author
-
Kaneda K, Kojima K, Takeuchi M, Takimoto H, Takaba S, Shinagawa K, Kobayashi H, Miyata A, Hara M, and Tanimoto M
- Subjects
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, Disease-Free Survival, Female, Humans, Leukemia diagnosis, Leukemia physiopathology, Male, Middle Aged, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes physiopathology, Retrospective Studies, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Leukemia classification, Leukemia genetics, Myelodysplastic Syndromes classification, Myelodysplastic Syndromes genetics, Translocation, Genetic
- Abstract
The new World Health Organization (WHO) classification of hematologic malignancies has incorporated t(8;21) myelodysplastic syndromes (MDS) according to the French-American-British classification into the category of acute myeloid leukemia (AML) with t(8;21)(q22;q22), while our knowledge about clinicopathological features of t(8;21) oligoblastic leukemia is still limited. We present our experience with 12 patients meeting the FAB diagnostic criteria of MDS and having t(8;21), who were compared to 43 t(8;21) AML patients. The MDS and AML patients shared most hematomorphologic, immunophenotypic, and clinical features, whereas the differences lay along myeloid maturation. The MDS patients had higher percentages of circulating neutrophils and marrow myeloid cells beyond promyelocytes than the AML patients. The incidence of Auer rods in mature neutrophils in MDS was significantly higher than that in AML, and furthermore, the neutrophils in MDS more commonly contain t(8;21) than in AML. Our findings support the rationale for the WHO classification, and future studies on large patient populations should help clarify whether the spontaneous differentiation potential could be actively associated with a hematological manifestation of t(8;21) leukemias.
- Published
- 2002
- Full Text
- View/download PDF